BioSpace News Archive

Kesin Pharma Corporation, a pharmaceutical company focused on innovative Specialty brands and Unit Dose formulations, announced today that the U.S. Food and Drug Administration (FDA) has approved LIKMEZ™ (metronidazole) oral suspension, 500 mg/5 mL.

EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, announced that it plans to move its U.S. Healthcare headquarters, currently located in Rockland, Mass., to Boston’s Seaport district.

BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the three months ended September 30, 2023, and reported on recent corporate developments.

At this year’s American College of Rheumatology annual meeting, Hospital for Special Surgery presented a number of important studies focused on reproductive health for patients with systemic lupus erythematosus, rheumatoid arthritis, and other rheumatic diseases, including issues related to fertility, sexual function, use of contraception and HPV vaccination.

Atsena Therapeutics today announced the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to ATSN-101, the company’s lead investigational gene therapy for patients with Leber congenital amaurosis caused by biallelic mutations in GUCY2D (LCA1).

QSAM Biosciences Inc. has signed a non-binding term sheet with Telix Pharmaceuticals Inc., a subsidiary of Telix Pharmaceuticals Limited providing material terms for the acquisition of the Company by Telix by means of a merger.

PDS Biotechnology Corporation today announced its financial results for the quarter ended September 30, 2023.

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced financial results for its fiscal first quarter ended September 30, 2023, and provided a corporate update.

Syros Pharmaceuticals today reported financial results for the quarter ended September 30, 2023 and provided a corporate update.

IMUNON, Inc. announced financial results for the three and nine months ended September 30, 2023.